IsoRay (ISR) Stock Is Falling | Not For Long!


IsoRay ISR Stock NewsIsoRay, Inc. (NYSEMKT: ISR)

IsoRay stock had an incredible day in the market yesterday; showing gains of more than 100%. However, today the story seems to have changed. Unfortunately, the trend has turned directions and the value of the stock is falling. While some investors are starting to become a bit concerned, I have to say that I’m not concerned at all. Today, we’ll talk about why the stock climbed yesterday, why I’m not even the slightest bit concerned about today’s declines, and what we can expect to see from ISR moving forward.

Why IsoRay Stock Climbed Yesterday

The climb yesterday was the result of the release of astonishing data showing that Cesium-131 was effective in small-cell lung cancer patients. Here’s what IsoRay CEO, Dwight Babckock had to say…

We are extremely excited to have our Cesium-131 isotope seeds and mesh used in the treatment of non-small cell lung cancers with such outstanding patient outcomes. Notable physicians, including the authors of this study, are seeking better solutions and outcomes for their patients. We are continuing to develop our product offerings internally with support from these industry leaders. With every success that has been reported, the medical community is rapidly becoming aware of the innovative alternative our Cesium-131 products offer to cancer patients.”

As a result of this release, the stock climbed by more than 100% in a single day. The simple fact is that this is another notch in the belt for Cesium-131; a product that’s likely to become incredibly profitable.

What We’re Seeing In The Market Today

Today however, the tides seem to have changed. IsoRay’s stock is on the decline, and in a big way. Currently (12:05), the stock is trading at $2.34 per share after a loss of 25.00% so far. While this may prove to be incredibly concerning to some, I have to say that I’m not concerned about today’s declines at all. One thing that’s important to remember when investing or trading is the fact that price movement in the market is a series of overreactions. This is especially true in the biotech space.

If you’re looking for negative news about Cesium-131 or ISR as a whole, stop looking, it’s a waste of time. The declines aren’t based on a fundamental flaw. Instead, yesterday’s gains were a bit of an overreaction; so, the market is doing what it does best today. It’s correcting in order to set up for more growth. With that said, I don’t see this as a concern, I see it as an opportunity!

What We Can Expect To See Moving Forward

I think we’re going to see quite a bit of positivity in both the short and long term outlooks. Here’s how I see it…

  • Short Term – In the short term ISR is in the midst of a small correction. However, it’s only gearing up for more gains. While we may be down today, I’m expecting to see the value of the stock pop back up within the coming days!

  • Long Term – In the long run, ISR is a fundamentally sound company. Their management has proven that it’s capable of staying on path and the innovation presented by their scientist and physicians is nothing short of amazing. So, I’m expecting to see long run gains for the stock!

What Do You Think?

Where do you think ISR is headed and why? Let us know in the comments below!


  1. Sir, great read.

    What are your thoughts on Adam Feuerstein attacks on ISR today? It was a peer review, but he is calling what Isoray wrote press release a “Fake”.



Please enter your comment!
Please enter your name here